查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1998465

植入用HLA型檢測市場：全球市場按產品類型、技術、植入類型、應用和最終用戶分類的預測——2026-2032年

HLA Typing for Transplant Market by Product Type, Technology, Transplant Type, Application, End user - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年用於植入的HLA型檢測市場價值為 11.8 億美元，預計到 2026 年將成長至 12.9 億美元，複合年成長率為 9.37%，到 2032 年將達到 22.2 億美元。

主要市場統計數據
基準年 2025 11.8億美元
預計年份：2026年 12.9億美元
預測年份 2032 22.2億美元
複合年成長率 (%) 9.37%

在過去十年間，組織相容性檢測已從人工血清學檢測發展到先進的分子檢測方法，與傳統方法相比，這些方法能夠在更短的時間內提供高度準確的結果。準確鑑定人類白血球抗原 (HLA) 圖譜是器官和幹細胞移植成功的關鍵。這決定了供體和受體的相容性，並指南免疫抑制治療。隨著全球移植數量的成長，對可靠、快速的HLA型檢測解決方案的需求也空前高漲。

聚合酵素鏈鎖反應(PCR) 技術與次世代定序技術的結合，將該領域的解析度提升到了前所未有的高度，使檢查室能夠以更高的靈敏度檢測罕見等位基因和複雜單倍型。此外，流式細胞技術和高通量電泳平台的進步簡化了工作流程，縮短了檢測結果的報告時間，並為關鍵的臨床決策提供了支援。監管機構也積極回應，並制定了嚴格的標準和認證流程，進一步推動了尖端調查方法。

此外，診斷技術與資訊學的融合正在創造一個以數據驅動的洞察來指導患者分層和風險評估的環境。包括移植中心、診斷檢查室和研究機構在內的移植生態系統中的相關人員，都在利用這些創新來最佳化配型流程並提高移植存活率。以下章節將深入探討本執行摘要中概述的、正在塑造移植領域HLA型檢測未來的變革性變化、收費系統影響、細分洞察和策略建議。

對影響移植中HLA型檢測實踐的顛覆性創新、技術突破和不斷演變的臨床工作流程進行詳細分析。

HLA型檢測調查方法的創新徹底改變了傳統的診斷流程，並顯著提升了處理能力和品質。攜帶式PCR系統和桌上型定序儀的出現，使得高解析度分型更加普及，即使是小規模中心也能在內部進行複雜的檢測。此外，人工智慧（AI）和機器學習演算法在軟體平台中的應用，提高了基因型解讀的準確性，減少了人工干預，並將人為錯誤的風險降至最低。

評估 2025 年美國關稅對HLA型檢測供應鏈、採購成本和營運永續性。

2025年，美國對進口實驗室設備和耗材徵收關稅，這為診斷檢查室的籌資策略帶來了重大轉變。對流式細胞儀、定序儀和電泳系統等高精度設備的關稅增加了購置成本，迫使各機構重新評估供應商合約。此外，試劑和專用耗材的關稅也導致單次檢測成本上升，影響了移植中心和研究機構的預算分配。

透過對產品類型、技術、移植、應用和最終用戶進行詳細分析，揭示HLA型檢測的策略見解。

在進行市場區隔時，本分析首先從涵蓋廣泛產品的產品類型，這些產品類別涵蓋從硬體平台到軟體解決方案的各個方面。儀器是HLA型檢測工作流程的核心，包括用於快速分離等位基因的電泳系統、針對高通量細胞分析最佳化的流式細胞儀、確保精確擴增的聚合酵素鏈鎖反應（PCR）系統，以及能夠以高解析度解碼複雜遺傳訊息的定序儀。與這些硬體設備相輔相成的是支援檢測特異性和一致性的試劑和耗材，以及便於資料解讀、儲存和報告的專用軟體套件。

對美洲、歐洲、中東和非洲以及亞太地區的HLA型檢測趨勢、機會和挑戰進行了全面研究。

區域分析揭示了美洲、歐洲、中東、非洲和亞太地區不同的發展趨勢，每個地區的趨勢都受到其獨特的監管環境、醫療基礎設施和投資環境的影響。在美洲，完善的報銷機制和成熟的移植中心網路促進了先進HLA型檢測解決方案的早期應用。北美市場受益於大量的公共和私人移植研究資金，而拉丁美洲國家則透過合作計畫和區域卓越中心逐步提升其診斷能力。

對推動HLA型檢測生態系統發展、夥伴關係和製定競爭策略的關鍵組織進行詳細評估。

在競爭日益激烈的市場環境下，主要企業正透過策略夥伴關係、產品組合拓展和精準創新來凸顯自身優勢。領先的儀器製造商正與軟體開發公司合作，提供整合解決方案，簡化樣品製備、數據收集和分析流程，從而縮短獲得結果所需的時間。在試劑領域，各公司正投資研發專有化學技術，以提高檢測靈敏度和重複性，從而更可靠地檢測低頻等位基因。

提高營運效率、促進合作、加速在臨床環境中採用下一代HLA型檢測解決方案的策略建議。

為了跟上不斷發展的HLA型檢測移植市場步伐，產業領導者應優先投資於工作流程自動化和數位整合。透過採用模組化平台，實現快速檢測規模化和無縫資料傳輸，檢查室可以在不影響品質的前提下提高處理能力。此外，與試劑供應商和分銷合作夥伴建立策略夥伴關係可以降低供應鏈風險，並確保關鍵組件的持續供應。

穩健的多階段研究途徑，詳細說明了資料收集、檢驗通訊協定、分析框架和品管—這是HLA型檢測市場研究的基礎。

本執行摘要的研究結合了第一手和第二手研究方法，以確保分析的全面性和可靠性。第一手研究包括對移植專家、實驗室管理人員和醫療採購專家進行詳細訪談，並輔以區域移植中心網路的問卷調查資料。這種直接參與使我們能夠深入觀點多個地區的營運挑戰、推廣促進因素和未滿足的需求。

整合關鍵研究成果，重點在於HLA型檢測植入技術發展趨勢中相關人員面臨的策略挑戰、未來前景和關鍵考量。

綜上所述，技術創新和臨床需求正在重塑移植領域HLA型檢測的模式。向高解析度分子檢測的轉變使得相容性評估更加精準，而軟體和自動化則縮短了檢測結果的報告時間並減少了人為錯誤。同時，貿易政策的變化，例如2025年關稅措施，正促使相關人員重新評估籌資策略並加強對供應鏈韌性的投入。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章： HLA型檢測在置入市場的應用：依產品類型分類

  • 裝置
    • 電泳裝置
    • 流式細胞儀
    • PCR系統
    • 序列器
  • 試劑和耗材
  • 軟體

第9章： HLA型檢測在植入市場的應用：依技術分類

  • 分子檢測
    • 次世代定序（NGS）
    • PCR方法
    • 桑格定序
  • 非分子方法
    • 混合淋巴球培養（MLC）
    • 血清學檢測

第10章： HLA型檢測在植入式醫療器材市場的應用－依植入類型分類

  • 造血幹細胞移植（HSCT）
    • 骨髓
    • 周邊血幹細胞
  • 固態器官移植
    • 心
    • 腎
    • 肝
    • 肺

第11章：用於植入的HLA型檢測市場：依應用領域分類

  • 疾病相關研究
  • 供受者匹配
  • 藥物基因體學學調查
  • 移植診斷

第12章：攜帶式HLA型檢測市場：依最終用戶分類

  • 血庫和器官捐贈者
  • 診斷檢查室
  • 醫院及移植中心
  • 研究所

第13章： HLA型檢測在植入市場的應用：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章： HLA型檢測在植入市場的應用：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章： HLA型檢測在植入市場的應用：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國植入的HLA型檢測市場

第17章：中國用於移植的HLA型檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biofortuna Limited
  • bioMerieux SA
  • Bruker Corporation
  • CareDx, Inc.
  • Creative Biolabs
  • Diasorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fujirebio Inc.
  • GenDx BV
  • HistoGenetics LLC
  • Hologic, Inc.
  • Illumina, Inc.
  • Immucor, Inc. by WERFEN
  • Omixon Biocomputing Ltd.
  • PacBio
  • QIAGEN NV
  • Siemens Healthineers AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-3D2FD205B873

The HLA Typing for Transplant Market was valued at USD 1.18 billion in 2025 and is projected to grow to USD 1.29 billion in 2026, with a CAGR of 9.37%, reaching USD 2.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.18 billion
Estimated Year [2026] USD 1.29 billion
Forecast Year [2032] USD 2.22 billion
CAGR (%) 9.37%

Over the past decade, histocompatibility testing has evolved from manual serological assays to sophisticated molecular approaches that deliver highly accurate results in a fraction of the time required by traditional methods. At the heart of successful organ and stem cell transplantation lies the precise identification of human leukocyte antigen (HLA) profiles, which dictates donor recipient compatibility and informs immunosuppressive regimens. As transplantation counts rise globally, the demand for reliable and rapid HLA typing solutions has never been greater.

The integration of polymerase chain reaction techniques with next-generation sequencing has propelled the field toward unprecedented resolution, enabling laboratories to detect rare alleles and complex haplotypes with superior sensitivity. Moreover, advancements in flow cytometry and high-throughput electrophoresis platforms have streamlined workflows and reduced turnaround times, supporting critical clinical decision making. Regulatory bodies have responded by establishing rigorous standards and accreditation pathways, further legitimizing the adoption of cutting-edge methodologies.

Furthermore, the convergence of diagnostic technologies with informatics has fostered an environment in which data-driven insights guide patient stratification and risk assessment. Stakeholders across the transplant ecosystem, including transplant centers, diagnostic laboratories, and research institutions, are leveraging these innovations to optimize matching processes and improve graft survival. In the following sections, this executive summary delves into transformative shifts, tariff impacts, segmentation insights, and strategic recommendations that will shape the future of HLA typing for transplant.

In-Depth Analysis of Disruptive Innovations, Technological Breakthroughs, and Evolving Clinical Workflows Shaping HLA Typing Practices Across Transplantation

Innovation in HLA typing methodologies has disrupted conventional diagnostic workflows, yielding improvements in throughput and quality. The advent of portable PCR systems and benchtop sequencers has democratized access to high-resolution typing, enabling smaller centers to conduct complex assays on site. In addition, the integration of artificial intelligence and machine learning algorithms into software platforms has enhanced genotype interpretation, reducing manual intervention and minimizing the risk of human error.

Furthermore, the migration toward cloud-based informatics solutions has accelerated data sharing among transplant networks, facilitating collaborative analysis and benchmarking. As laboratories adopt automated liquid handling and robotics, process variability has diminished and sample processing capacity has expanded, meeting the growing volumes of transplant evaluations. Regulatory frameworks are adapting in parallel, offering streamlined pathways for software-driven diagnostics while maintaining robust validation requirements.

Consequently, the landscape of HLA typing is becoming increasingly interconnected, with interoperable systems that link laboratory information management, electronic health records, and patient registries. These advancements not only improve clinical efficiency but also support real-time surveillance of transplant outcomes and population-level HLA diversity. In view of these trends, stakeholders must remain agile and embrace novel technologies to sustain competitive advantage and deliver superior patient care.

Evaluating the Far-Reaching Consequences of 2025 United States Tariffs on Supply Chains, Procurement Costs, and Operational Viability in HLA Typing

In 2025, the introduction of tariffs on imported laboratory instruments and consumables in the United States has introduced a significant variable into the procurement strategies of diagnostic laboratories. Tariffs applied to high-precision equipment such as flow cytometers, sequencers, and electrophoresis systems have driven up acquisition costs, compelling organizations to reevaluate vendor agreements. Moreover, duties on reagents and specialized consumables have translated into higher per-test expenses, affecting budget allocations for transplant centers and research facilities alike.

Supply chain resilience has become a paramount concern as manufacturers navigate shifting trade barriers and lead time uncertainties. Many laboratories have pursued alternative sourcing strategies, including partnerships with domestic suppliers or stockpiling critical reagents to mitigate potential shortages. In parallel, some instrument vendors have relocated certain production processes closer to end markets or introduced fee structures designed to offset the impact of import taxes.

These cumulative effects have created a dual imperative: laboratories must optimize resource utilization while maintaining the high accuracy and throughput standards that are essential for transplant compatibility assessments. As stakeholders adapt, collaborative purchasing consortia and local distribution hubs are emerging to leverage economies of scale and reduce the administrative burden associated with tariff compliance.

At the same time, the tariff environment has prompted a renewed focus on developing cost-effective consumables and open platform systems that offer greater flexibility in component sourcing. Strategic alliances between instrument manufacturers and local distributors are enabling a more agile response to regulatory changes, while cross-border collaborations seek to harmonize quality benchmarks and certification requirements. As the sector adjusts to this altered cost structure, long-term planning must incorporate scenario analyses that account for both tariff fluctuations and evolving global trade policies.

Illuminating Strategic Insights Through Detailed Analysis of Product, Technology, Transplant, Application, and End User Segmentation in HLA Typing

In considering market segmentation, the analysis begins with product categories that encompass a range of offerings from hardware platforms to software solutions. Instruments represent the backbone of HLA typing workflows and include electrophoresis equipment designed for rapid allele separation, flow cytometers optimized for high-throughput cell analysis, polymerase chain reaction systems that ensure precise amplification, and sequencers capable of decoding complex genetic information with high resolution. Complementing these physical assets are reagents and consumables that support assay specificity and consistency, as well as specialized software suites that facilitate data interpretation, storage, and reporting.

Technology segmentation distinguishes molecular assays, which leverage methodologies such as next-generation sequencing for comprehensive allele profiling, PCR-based techniques for targeted amplification, and Sanger sequencing for confirmatory analysis, from non-molecular assays that rely on mixed lymphocyte culture to assess cellular reactivity and serological approaches to detect antigen presence through antibody interactions. Each category delivers unique advantages in terms of throughput, cost, and resolution, catering to diverse laboratory requirements.

Transplant type segmentation draws a distinction between hematopoietic stem cell transplantation and solid organ transplantation. The former includes both bone marrow and peripheral blood stem cell applications, where rapid typing is critical to patient outcomes. The latter encompasses heart, kidney, liver, and lung transplants, each demanding tailored HLA matching criteria and risk assessment protocols. Application segmentation captures the spectrum of research and clinical use cases, spanning disease association studies that explore genetic predispositions, donor recipient matching processes that underpin graft acceptance, pharmacogenomics research informing individualized therapies, and transplant diagnostics that guide perioperative management.

Finally, end users range from blood banks and organ procurement organizations that manage donor registries to diagnostic laboratories equipped for high-complexity testing, hospitals and transplant centers overseeing patient pathways, and research laboratories driving innovation. Understanding these nuanced segments is essential for stakeholders seeking to align product development, marketing strategies, and service offerings with the specific needs and priorities of each customer group.

Comprehensive Examination of Regional Dynamics, Opportunities, and Challenges Across the Americas, Europe Middle East Africa, and Asia-Pacific in HLA Typing

Regional analysis reveals distinct trajectories across the Americas, Europe Middle East Africa, and Asia-Pacific, each shaped by unique regulatory landscapes, healthcare infrastructure, and investment climates. In the Americas, established reimbursement pathways and a mature network of transplant centers have fostered early adoption of advanced HLA typing solutions. Key markets in North America benefit from significant public and private funding for transplant research, while Latin American countries are gradually expanding diagnostic capacities through collaborative programs and regional centers of excellence.

In Europe, Middle East, and Africa, harmonization of regulatory standards within the European Union has accelerated the availability of novel assays, yet variability persists across member states in terms of coverage and reimbursement. In the Middle East, growing healthcare modernization initiatives and the establishment of specialized transplant units are driving demand for high-resolution typing, whereas resource constraints in parts of Africa underscore the need for scalable and cost-effective testing models.

Across the Asia-Pacific region, rapid investments in healthcare infrastructure and rising prevalence of transplant procedures are catalyzing market growth. Markets in East Asia demonstrate strong uptake of next-generation sequencing, supported by local manufacturing capabilities and research partnerships. Meanwhile, Southeast Asian countries are enhancing laboratory networks through government-led health reforms, and Australasia continues to lead in the integration of informatics platforms that link transplant registries with diagnostic results. These regional dynamics highlight both opportunities for targeted expansion and the importance of adaptable strategies in a diverse global environment.

In-Depth Assessment of Leading Organizations Driving Advances, Partnerships, and Competitive Strategies in the HLA Typing Ecosystem

In an increasingly competitive landscape, leading organizations are differentiating through a combination of strategic partnerships, portfolio expansion, and targeted innovation. Major instrument manufacturers are collaborating with software developers to deliver integrated solutions that streamline sample preparation, data acquisition, and analysis, reducing overall time to result. At the reagent level, companies are investing in proprietary chemistries that enhance assay sensitivity and reproducibility, enabling more reliable detection of low-frequency alleles.

Furthermore, several players are pursuing acquisitions that bolster their presence in emerging markets or expand capabilities into complementary diagnostic areas such as immunogenetics and pharmacogenomics. Concurrently, specialized firms are carving out niches by focusing exclusively on high-resolution sequencing assays, offering customizable panels that cater to unique transplantation protocols. These developments are underpinned by ongoing research collaborations with academic and clinical institutions, fostering a pipeline of next-generation platforms and novel biomarkers.

Collectively, these strategies reflect a shift toward end-to-end solutions that support the full lifecycle of HLA typing services. As competition intensifies, organizations that can effectively integrate hardware, consumables, software, and support services stand to gain a sustainable advantage in both established and developing markets.

Strategic Recommendations to Enhance Operational Efficiency, Foster Collaboration, and Accelerate Adoption of Next-Generation HLA Typing Solutions in Clinical Settings

To navigate the evolving HLA typing for transplant market, industry leaders should prioritize investments in workflow automation and digital integration. By adopting modular platforms that facilitate rapid assay expansion and seamless data transfer, laboratories can achieve greater throughput without compromising quality. In addition, forging strategic alliances with reagent suppliers and distribution partners will mitigate supply chain risks and ensure uninterrupted access to critical components.

Embracing open data standards and interoperable informatics infrastructures will enhance collaboration between transplant centers, diagnostic laboratories, and research networks, driving deeper insights and improved patient outcomes. Leaders should also explore opportunities in emerging markets by tailoring solutions to local epidemiological profiles, regulatory requirements, and budgetary constraints. Workforce development initiatives, including training programs for technical staff and bioinformatics specialists, are essential to maximize the potential of advanced typing methodologies.

Finally, engaging with regulatory agencies to shape evolving accreditation frameworks can streamline the pathway for novel technologies, while participation in professional consortia and standards committees will position organizations at the forefront of best practices. These actionable steps will empower stakeholders to capitalize on technological advances, optimize operational efficiencies, and deliver enhanced value across the transplant ecosystem.

Robust Multi-Phase Research Approach Detailing Data Collection, Validation Protocols, Analytical Frameworks, and Quality Controls Underpinning the HLA Typing Market Study

The research underpinning this executive summary combines primary and secondary methodologies to ensure a comprehensive and reliable analysis. Primary research involved in-depth interviews with transplantation experts, laboratory directors, and healthcare procurement specialists, supplemented by survey data from regional networks of transplant centers. This direct engagement provided nuanced perspectives on operational challenges, adoption drivers, and unmet needs across multiple geographies.

Secondary research encompassed a systematic review of peer-reviewed journals, regulatory filings, clinical guidelines, and technical white papers. Data extraction protocols were designed to capture the latest advancements in assay technologies, workflow innovations, and regulatory developments. Triangulation methods were employed to cross-verify findings, enhancing the accuracy of insights and minimizing potential biases.

Analytical frameworks included a strengths, weaknesses, opportunities, and threats examination of key segments, as well as a five forces assessment of the competitive environment. Quality control measures consisted of expert panel reviews and iterative validation cycles to refine conclusions. Together, these rigorous methods combine to deliver a robust foundation for strategic decision making within the HLA typing for transplant domain.

Synthesis of Core Findings Emphasizing Strategic Imperatives, Future Outlook, and Key Considerations for Stakeholders in the Evolving HLA Typing for Transplant Landscape

In synthesizing the core findings, it is evident that technological innovation and clinical demand are converging to redefine the HLA typing landscape for transplantation. The shift toward high-resolution, molecular-based assays is enabling more precise compatibility assessments, while software and automation are accelerating turnaround times and reducing manual errors. Simultaneously, evolving trade policies, exemplified by the 2025 tariffs, have prompted stakeholders to reevaluate procurement strategies and invest in supply chain resilience.

Segmentation analysis offers a granular understanding of market drivers across product, technology, transplant type, application, and end-user categories, guiding tailored approaches to product development and commercialization. Regional insights further contextualize these trends, highlighting the need for adaptable strategies that address the diverse regulatory, infrastructural, and economic conditions present in the Americas, Europe Middle East Africa, and Asia-Pacific. Leading organizations are responding through integrated offerings and strategic collaborations, setting the stage for differentiated growth.

Looking ahead, the successful navigation of regulatory landscapes, combined with targeted investments in digital and automated solutions, will be paramount to advancing transplant outcomes and driving market success. Stakeholders equipped with these insights will be well positioned to respond to emerging opportunities and maintain a competitive edge in the dynamic field of HLA typing for transplant.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HLA Typing for Transplant Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Electrophoresis Equipment
    • 8.1.2. Flow Cytometers
    • 8.1.3. PCR Systems
    • 8.1.4. Sequencers
  • 8.2. Reagents & Consumables
  • 8.3. Software

9. HLA Typing for Transplant Market, by Technology

  • 9.1. Molecular Assays
    • 9.1.1. Next-Generation Sequencing (NGS)
    • 9.1.2. PCR-based Methods
    • 9.1.3. Sanger Sequencing
  • 9.2. Non-molecular Assays
    • 9.2.1. Mixed Lymphocyte Culture (MLC)
    • 9.2.2. Serological Assays

10. HLA Typing for Transplant Market, by Transplant Type

  • 10.1. Hematopoietic Stem Cell Transplant (HSCT)
    • 10.1.1. Bone Marrow
    • 10.1.2. Peripheral Blood Stem Cells
  • 10.2. Solid Organ Transplant
    • 10.2.1. Heart
    • 10.2.2. Kidney
    • 10.2.3. Liver
    • 10.2.4. Lung

11. HLA Typing for Transplant Market, by Application

  • 11.1. Disease Association Studies
  • 11.2. Donor Recipient Matching
  • 11.3. Pharmacogenomics Research
  • 11.4. Transplant Diagnostics

12. HLA Typing for Transplant Market, by End user

  • 12.1. Blood Banks & Organ Procurement Organizations
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Transplant Centers
  • 12.4. Research Laboratories

13. HLA Typing for Transplant Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. HLA Typing for Transplant Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. HLA Typing for Transplant Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States HLA Typing for Transplant Market

17. China HLA Typing for Transplant Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Biofortuna Limited
  • 18.10. bioMerieux SA
  • 18.11. Bruker Corporation
  • 18.12. CareDx, Inc.
  • 18.13. Creative Biolabs
  • 18.14. Diasorin S.p.A.
  • 18.15. F. Hoffmann-La Roche Ltd
  • 18.16. Fujirebio Inc.
  • 18.17. GenDx B.V.
  • 18.18. HistoGenetics LLC
  • 18.19. Hologic, Inc.
  • 18.20. Illumina, Inc.
  • 18.21. Immucor, Inc. by WERFEN
  • 18.22. Omixon Biocomputing Ltd.
  • 18.23. PacBio
  • 18.24. QIAGEN N.V.
  • 18.25. Siemens Healthineers AG
  • 18.26. Takara Bio Inc.
  • 18.27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ELECTROPHORESIS EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ELECTROPHORESIS EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ELECTROPHORESIS EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MIXED LYMPHOCYTE CULTURE (MLC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MIXED LYMPHOCYTE CULTURE (MLC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MIXED LYMPHOCYTE CULTURE (MLC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEROLOGICAL ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEROLOGICAL ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEROLOGICAL ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PERIPHERAL BLOOD STEM CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PERIPHERAL BLOOD STEM CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PERIPHERAL BLOOD STEM CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DISEASE ASSOCIATION STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DISEASE ASSOCIATION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DISEASE ASSOCIATION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DONOR RECIPIENT MATCHING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PHARMACOGENOMICS RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PHARMACOGENOMICS RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PHARMACOGENOMICS RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BLOOD BANKS & ORGAN PROCUREMENT ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BLOOD BANKS & ORGAN PROCUREMENT ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY BLOOD BANKS & ORGAN PROCUREMENT ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 211. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 212. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 233. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 241. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 242. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 244. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 245. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. G7 HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 253. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 255. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 256. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. NATO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), 2018-2032 (USD MILLION)
  • TABLE 278. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOLID ORGAN TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)